Inhibition of NAMPT pathway by FK866 activates the function of p53 in HEK293T cells

Biochemical and Biophysical Research Communications

Volumn 424, Issue 3, 2012, Pages 371-377

  Thakur, Basant Kumar ^a   Dittrich, Tino ^a   Chandra, Prakash ^b   Becker, Annette ^c   Lippka, Yannick ^a   Selvakumar, Divakarvel ^a,d   Klusmann, Jan Henning ^a   Reinhardt, Dirk ^a   Welte, Karl ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

^b GOETHE UNIVERSITY MEDICAL SCHOOL   (Germany)

^c DARMSTADT UNIVERSITY OF TECHNOLOGY   (Germany)

^d RUTGERS UNIVERSITY   (United States)

Author keywords

Acetylation; NAMPT and FK866; P53; SV 40; T antigen

Indexed keywords

DAPORINAD; NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE; PROTEIN P53;

ACETYLATION; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CELL COUNT; CELL CYCLE ARREST; CELL CYCLE S PHASE; CELL PROLIFERATION; CELL STRAIN HEK293; CONTROLLED STUDY; DRUG EFFECT; EMBRYO; HUMAN; HUMAN CELL; PRIORITY JOURNAL;

ACETYLATION; ACRYLAMIDES; APOPTOSIS; CELL CYCLE; CYTOKINES; ENZYME INHIBITORS; GENE KNOCKDOWN TECHNIQUES; HEK293 CELLS; HUMANS; LYSINE; METABOLIC NETWORKS AND PATHWAYS; NEOPLASMS; NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE; PIPERIDINES; SIMIAN VIRUS 40; SIRTUIN 1; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84864777092     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2012.06.075     Document Type: Article

References (24)

1. Jasani B., Cristaudo A., Emri S.A., Gazdar A.F., Gibbs A., Krynska B., Miller C., Mutti L., Radu C., Tognon M., Procopio A. Association of SV40 with human tumours. Semin. Cancer Biol. 2001, 11:49-61.
2. Ahuja D., Saenz-Robles M.T., Pipas J.M. SV40 large T antigen targets multiple cellular pathways to elicit cellular transformation. Oncogene 2005, 24:7729-7745.
3. Bargonetti J., Reynisdottir I., Friedman P.N., Prives C. Site-specific binding of wild-type p53 to cellular DNA is inhibited by SV40 T antigen and mutant p53. Genes Dev. 1992, 6:1886-1898.
4. Lilyestrom W., Klein M.G., Zhang R., Joachimiak A., Chen X.S. Crystal structure of SV40 large T-antigen bound to p53: interplay between a viral oncoprotein and a cellular tumor suppressor. Genes Dev. 2006, 20:2373-2382.
5. Carbone M., Rudzinski J., Bocchetta M. High throughput testing of the SV40 Large T antigen binding to cellular p53 identifies putative drugs for the treatment of SV40-related cancers. Virology 2003, 315:409-414.
6. Deppert W., Haug M. Evidence for free and metabolically stable p53 protein in nuclear subfractions of simian virus 40-transformed cells. Mol. Cell. Biol. 1986, 6:2233-2240.
7. Meek D.W., Anderson C.W. Posttranslational modification of p53: cooperative integrators of function. Cold Spring Harb. Perspect Biol. 2009, 1(6):a000950.
8. Khan O., La Thangue N.B. HDAC inhibitors in cancer biology: emerging mechanisms and clinical applications. Immunol. Cell Biol. 2012, 90:85-94.
9. Revollo J.R., Grimm A.A., Imai S. The NAD biosynthesis pathway mediated by nicotinamide phosphoribosyltransferase regulates Sir2 activity in mammalian cells. J. Biol. Chem. 2004, 279:50754-50763.
10. Zhang T., Berrocal J.G., Frizzell K.M., Gamble M.J., DuMond M.E., Krishnakumar R., Yang T., Sauve A.A., Kraus W.L. Enzymes in the NAD+ salvage pathway regulate SIRT1 activity at target gene promoters. J. Biol. Chem. 2009, 284:20408-20417.
11. Vaziri H., Dessain S.K., Ng Eaton E., Imai S.I., Frye R.A., Pandita T.K., Guarente L., Weinberg R.A. HSIR2(SIRT1) functions as an NAD-dependent p53 deacetylase. Cell 2001, 107:149-159.
12. Luo J., Nikolaev A.Y., Imai S., Chen D., Su F., Shiloh A., Guarente L., Gu W. Negative control of p53 by Sir2alpha promotes cell survival under stress. Cell 2001, 107:137-148.
13. Langley E., Pearson M., Faretta M., Bauer U.M., Frye R.A., Minucci S., Pelicci P.G., Kouzarides T. Human SIR2 deacetylates p53 and antagonizes PML/p53-induced cellular senescence. EMBO J. 2002, 21:2383-2396.
14. Nahimana A., Attinger A., Aubry D., Greaney P., Ireson C., Thougaard A.V., Tjornelund J., Dawson K.M., Dupuis M., Duchosal M.A. The NAD biosynthesis inhibitor APO866 has potent antitumor activity against hematologic malignancies. Blood 2009, 113:3276-3286.
15. van der Veer E., Ho C., O'Neil C., Barbosa N., Scott R., Cregan S.P., Pickering J.G. Extension of human cell lifespan by nicotinamide phosphoribosyltransferase. J. Biol. Chem. 2007, 282:10841-10845.
16. Pipas J.M., Levine A.J. Role of T antigen interactions with p53 in tumorigenesis. Semin. Cancer Biol. 2001, 11:23-30.
17. Brown D.R., Deb S., Munoz R.M., Subler M.A., Deb S.P. The tumor suppressor p53 and the oncoprotein simian virus 40 T antigen bind to overlapping domains on the MDM2 protein. Mol. Cell. Biol. 1993, 13:6849-6857.
18. Tang Y., Zhao W., Chen Y., Zhao Y., Gu W. Acetylation is indispensable for p53 activation. Cell 2008, 133:612-626.
19. Skokowa J., Lan D., Thakur B.K., Wang F., Gupta K., Cario G., Brechlin A.M., Schambach A., Hinrichsen L., Meyer G., Gaestel M., Stanulla M., Tong Q., Welte K. NAMPT is essential for the G-CSF-induced myeloid differentiation via a NAD(+)-sirtuin-1-dependent pathway. Nat. Med. 2009, 15:151-158.
20. Bitterman K.J., Anderson R.M., Cohen H.Y., Latorre-Esteves M., Sinclair D.A. Inhibition of silencing and accelerated aging by nicotinamide, a putative negative regulator of yeast sir2 and human SIRT1. J. Biol. Chem. 2002, 277:45099-45107.
21. Bogan K.L., Brenner C. Nicotinic acid, nicotinamide, and nicotinamide riboside: a molecular evaluation of NAD+ precursor vitamins in human nutrition. Annu. Rev. Nutr. 2008, 28:115-130.
22. Hasmann M., Schemainda I. FK866, a highly specific noncompetitive inhibitor of nicotinamide phosphoribosyltransferase, represents a novel mechanism for induction of tumor cell apoptosis. Cancer Res. 2003, 63:7436-7442.
23. Schemies J., Uciechowska U., Sippl W., Jung M. NAD(+) -dependent histone deacetylases (sirtuins) as novel therapeutic targets. Med. Res. Rev. 2010, 30:861-889.
24. Thakur B.K., Lippka Y., Dittrich T., Chandra P., Skokowa J., Welte K. NAMPT pathway is involved in the FOXO3a-mediated regulation of GADD45A expression. Biochem. Biophys. Res. Commun. 2012, 420:714-720.